Nuvectis Pharma, Inc.
NVCT
$6.46
$0.6511.19%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.38M | -22.07M | -20.16M | -19.00M | -19.37M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.70M | 5.40M | 4.93M | 4.86M | 4.94M |
| Change in Net Operating Assets | 5.18M | 4.26M | 3.17M | 1.90M | 805.00K |
| Cash from Operations | -14.50M | -12.41M | -12.06M | -12.25M | -13.63M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 34.92M | 22.87M | 23.99M | 12.04M | 8.98M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.14M | -1.79M | -1.52M | -382.00K | -242.00K |
| Cash from Financing | 32.77M | 21.09M | 22.46M | 11.65M | 8.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.27M | 8.68M | 10.40M | -593.00K | -4.89M |